Phase III AGMT NHL13 Trial of Rituximab Maintenance versus Observation in Aggressive B-Cell Lymphoma


Phase III AGMT NHL13 Trial of Rituximab Maintenance versus Observation in Aggressive B-Cell Lymphoma
Slides from a presentation at ICML 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (10/26/13)
Jaeger U et al. Rituximab maintenance treatment versus observation in patients with aggressive B-cell lymphoma: Results of the AGMT NHL13 trial. Proc ICML 2013;Abstract 119.

Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts University School of Medicine and Director of the Lymphoma Program and Leader of the Clinical Sciences Program at Tufts Cancer Center in Boston, Massachusetts.